Form 4: Gilead Sciences Chief Commercial Officer Reports Routine Equity Transactions

Gilead Sciences, Inc.'s Chief Commercial Officer, Johanna Mercier, reported the vesting of restricted stock units and a subsequent sale of shares for tax withholding purposes.

Summary

• Johanna Mercier, Chief Commercial Officer of Gilead Sciences, Inc. (GILD), reported transactions on June 10, 2025.
• Mercier acquired 3,843 shares of Gilead Sciences common stock through the vesting of restricted stock units (RSUs).
• Concurrently, 1,827 shares of common stock were disposed of at a price of $110.09 per share to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Ms. Mercier beneficially owns 123,168 shares of Gilead Sciences common stock.
• Additionally, Ms. Mercier holds 35,360 unvested restricted stock units.
• The restricted stock units have a four-year vesting schedule, with 25% vesting on the first anniversary of the grant date, and the balance vesting at 6.25% quarterly thereafter.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine and expected insider transaction related to equity compensation, with no indication of significant positive or negative implications for the company's operations or financial health.

Positives

• The acquisition of 3,843 shares through RSU vesting indicates continued equity alignment between the Chief Commercial Officer and shareholder interests.
• The transaction is a routine vesting event, reflecting the company's compensation structure for executives.

Negatives

• A portion of the vested shares (1,827 shares) was sold to cover tax obligations, which represents a reduction in direct shareholding, although it is a common practice for RSU vesting.

Future Outlook

This Form 4 filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

This filing is a standard disclosure of an insider equity transaction, common across all publicly traded companies, and does not provide specific insights into broader industry trends or competitive dynamics within the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders: The transaction is a routine equity compensation event and tax-related sale, which is generally not expected to have a material impact on the company's stock price or shareholder value.
• Employees: Reflects standard executive compensation practices, which may be viewed positively as a retention mechanism.

Next Steps

• The remaining 35,360 restricted stock units held by Ms. Mercier will continue to vest according to the established four-year schedule, with quarterly vesting of 6.25% after the first anniversary.

Key Dates

Keywords

Gilead Sciences, GILD, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Equity Compensation, Chief Commercial Officer, Johanna Mercier, Stock Sale, Tax Withholding